Opaleye Management Dumps 140,000 Harrow Shares Amid Bear Market — Is Confidence in the Company Waning?

Insider Selling Surge at Harrow Inc.

The latest 4‑Form filing shows Opaleye Management Inc. liquidating a significant portion of its holdings in Harrow Inc., selling 59,000 shares at an average price of $39.15. This follows a series of prior sales in February and early March, with the fund’s stake falling from 70,000 to 3.8 million shares overall. The timing is notable: the company’s stock closed at $39.22 on the day of the filing, while the broader market has seen a steep 33 % weekly decline and a 23 % monthly drop, suggesting that the sales are occurring amid a bearish trend rather than a strategic divestment.

What Does This Mean for Investors? A sharp insider sell-off can signal a loss of confidence in the company’s near‑term prospects. Yet, the magnitude of the sales—over 140,000 shares in a single day—may be driven by portfolio rebalancing rather than a fundamental reversal. Analysts will scrutinize whether the selling correlates with impending disclosures, such as the Phase‑3 trial results for the preservative‑free triamcinolone. If the trial outcomes are unfavorable, the sales could presage a sharper price decline; conversely, a positive outcome could blunt the impact of the insider pressure.

Opaleye Management’s Historical Behavior Historically, Opaleye’s transactions have been predominantly sales, often executed at prices ranging from $53 to $54 per share in January and February, well above the current $39 range. The fund’s holdings have fluctuated from 70 million to 3.8 million shares, indicating a pattern of aggressive liquidation when market conditions shift. This behavior suggests that Opaleye acts as a tactical investor, harvesting gains in a volatile market rather than maintaining a long‑term position.

Company‑Wide Insider Activity Context Other insiders, including CEO Mark Baum and CFO Andrew Boll, have been active in both purchases and sales, with recent RSU acquisitions and large stock purchases in December 2025. These mixed signals underscore a broader insider confidence in Harrow’s long‑term trajectory, despite the current sell pressure from Opaleye. The contrast between executive accumulation and third‑party liquidation could temper investor fears, but the recent sell volume remains a red flag for short‑term sentiment.

Looking Ahead Harrow’s upcoming presentation at Leerink Partner’s 2026 Global Healthcare Conference and the pending Phase‑3 trial results will be critical data points. If the company can demonstrate robust clinical efficacy and secure FDA clearance, it may offset the negative signals from the insider sales. For now, investors should monitor the volatility around the $39 price level, weigh Opaleye’s historical sell patterns, and stay alert to any corporate announcements that could shift the narrative from short‑term sell‑pressure to long‑term growth prospects.